Chembio Enters Into Six-Month $480,000 Follow-On Contract With CDC Contractor for Point-of-Care Influenza Test Development MEDFORD, N.Y. , July 17, 2012 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a NY-based company that develops, manufactures, licenses and markets proprietary
Chembio Diagnostics Announces Positive Data From Independent Study of Rapid, Point-of-Care Hepatitis C Test Published in the Journal of Clinical Virology MEDFORD, NY, Jun 19, 2012 (MARKETWIRE via COMTEX) --Chembio Diagnostics, Inc. (NASDAQ: CEMI), a leader in point-of-care diagnostic tests for
Chembio Diagnostics Announces Positive Data From Independent Study of Rapid, Point-of-Care Hepatitis C Test Published in the Journal of Clinical Virology MEDFORD, NY, Jun 19, 2012 (MARKETWIRE via COMTEX) --Chembio Diagnostics, Inc. (NASDAQ: CEMI), a leader in point-of-care diagnostic tests for
Chembio to Ring Opening Bell Today on NASDAQ MEDFORD, NY, Jun 11, 2012 (MARKETWIRE via COMTEX) --Chembio Diagnostics, Inc. (NASDAQ: CEMI), which develops, manufactures, markets and licenses point-of-care diagnostic tests, reports that Chembio will visit The NASDAQ MarketSite in Times Square and
Chembio Files Final Module of Premarket Approval Application With FDA for DPP ® Point-of-Care HIV 1/2 Rapid Test MEDFORD, NY, Jun 07, 2012 (MARKETWIRE via COMTEX) --Chembio Diagnostics, Inc. (NASDAQ: CEMI) (OTCQB: CEMID) (PINKSHEETS: CEMI), which develops, manufactures, markets and licenses
Chembio Files Final Module of Premarket Approval Application With FDA for DPP(R) Point-of-Care HIV 1/2 Rapid Test MEDFORD, NY, Jun 07, 2012 (MARKETWIRE via COMTEX) --Chembio Diagnostics, Inc. (NASDAQ: CEMI) (OTCQB: CEMID) (PINKSHEETS: CEMI), which develops, manufactures, markets and licenses
Print Page